ad image

Metastatic Melanoma

1 / 1
Merck & Co.
Therapy Approval

KEYTRUDA® (pembrolizumab) is the First Anti-PD-1 Therapy Approved in China for Advanced Melanoma

Merck & Co.

PR-M07-18-NI-098Jul 30, 2018
1 / 1